Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-21-019157

Executive VP, Head of R&D gave up 1,585 shares (to pay taxes)

  • Executive VP, Head of R&D acquired 3,333 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Ho Tony W Executive VP, Head of R&D 2021-03-05 Option exercise +3,333 37,447 D
Ho Tony W Executive VP, Head of R&D 2021-03-05 Shares withheld for taxes −1,585 $114.65 $181,720 35,862 D
Loading xslF345X03/doc4.xml…